Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

NCT03099499 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Endometrial Cancer

Interventions

DRUG: ONC201

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]